肺癌的表皮生长因子受体分子靶向治疗与基因突变

被引：3

作者：

赵亚力

李琦

韩为东

机构：

[1] 解放军总医院基础医学研究所分子生物学研究室

来源：

生物技术通讯 | 2007年 / 06期

关键词：

肺癌; 分子靶向治疗; 表皮生长因子受体; 基因突变;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

肺癌分子靶向治疗近年来取得较大进展,特别是针对表皮生长因子受体(EGFR)分子靶向药物表现出确定的临床效果。临床应用表明,EGFR基因酪氨酸激酶域体细胞突变与非小细胞肺癌患者对酪氨酸激酶抑制剂吉非替尼的敏感性相关,本文就相关的研究进行了简述。

引用

页码：1007 / 1009

页数：3

共 22 条

[1]

PhaseⅡtrails of gefitinib(Iressa,ZD1839):rapid and durable objective responses in patientswith advanced non-small-cell lung cancer(IDEAL1 and IDEAL2). Fukuoka M,Kris M,Giaccone G,et al. Lung Cancer . 2003

[2]

The EGFR family and it s ligands in human cancer.signalling mechanisms and t herapeutic opport unities. Yarden Y. European Journal of Cancer . 2001

[3]

Why the epidermal growth factor receptor?The rational for cancer therapy. Baselga J. Oncologist, The . 2002

[4]

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. CAPPUZZO F,HIRSCH FR,ROSSI E, et al. Nati Cancer Ins . 2005

[5]

EGF receptor gene mutations are common in lung cancers from“never smokers”and are associated with sensitivity of tumors to gefitinib and erlotinib. Pao W,,Miller V,Zakowski M,et al. Proceedings of the National Academy of Sciences of the United States of America . 2004

[6]

A Randomized phase Ⅲ trial comparing bevacizumab/ carboplatin /paclitaxel versus carboplatin /paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Sandier AB,Gray R,Brahmer J, et al. Proceedings of the American Society of Clinical Oncology . 2005

[7] Somatic mutations in epidermal growth factor receptor underlying complete-responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung [J].

Yeh, KH ;

Yeh, SH ;

Wan, JP ;

Shen, YC ;

Cheng, AL .

ANTI-CANCER DRUGS, 2005, 16 (07) :739-742

[8]

Identification of EGFR kinasedomain mutations among lung cancer patients in China:implicationfor targeted cancer therapy. Qin BM,Chen X,Zhu JD,et al. Cell Research . 2005

[9]

Mutations of the epidermalgrowth factor receptor gene in lung cancer:biological and clinicalimplications. Kosaka T,Yatabe Y,Endoh H,et al. Cancer Research . 2004

[10]

P-615 Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAl 2)[J] . Masahiro Fukuoka,Mark Kris,Giuseppe Giaccone,Thomas Lynch,Kazuhiko Nakagawa,Karen Kelly,Michael Wolf,Angela McPartlane,Andrea Kay,Abderrahim Fandi. &nbspLung Cancer . 2003

← 1 2 3 →